<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Imagion Biosystems Ltd — News on 6ix</title>
<link>https://6ix.com/company/imagion-biosystems-ltd</link>
<description>Latest news and press releases for Imagion Biosystems Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 06:37:03 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/imagion-biosystems-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836668878dffbe2df15dfa3.webp</url>
<title>Imagion Biosystems Ltd</title>
<link>https://6ix.com/company/imagion-biosystems-ltd</link>
</image>
<item>
<title>Appendix 4C and Quarterly Activities Report - March 2026</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4c-and-quarterly-activities-report-march-2026</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4c-and-quarterly-activities-report-march-2026</guid>
<pubDate>Thu, 23 Apr 2026 06:37:03 GMT</pubDate>
<description>Appendix 4C and Quarterly Activities Report - March 2026</description>
</item>
<item>
<title>FY25 Appendix 4E and Annual Report</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/fy25-appendix-4e-and-annual-report-19</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/fy25-appendix-4e-and-annual-report-19</guid>
<pubDate>Fri, 27 Feb 2026 09:16:03 GMT</pubDate>
<description>FY25 Appendix 4E and Annual Report</description>
</item>
<item>
<title>Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/medical-imaging-company-imagion-biosystems-163000959</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/medical-imaging-company-imagion-biosystems-163000959</guid>
<pubDate>Tue, 03 Feb 2026 16:30:00 GMT</pubDate>
<description>MELBOURNE, Australia, February 03, 2026--Imagion Biosystems, Ltd. announced that the company has lodged an IND application with the FDA for its MagSense® targeted imaging agent.</description>
</item>
<item>
<title>IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/ibxs-ind-application-lodged-with-fda-for-her2-phase-2-trial</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/ibxs-ind-application-lodged-with-fda-for-her2-phase-2-trial</guid>
<pubDate>Mon, 02 Feb 2026 03:38:06 GMT</pubDate>
<description>IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial</description>
</item>
<item>
<title>Appendix 4C and Quarterly Activities Report - December 2025</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4c-and-quarterly-activities-report-december-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4c-and-quarterly-activities-report-december-2025-1</guid>
<pubDate>Thu, 29 Jan 2026 04:11:06 GMT</pubDate>
<description>Appendix 4C and Quarterly Activities Report - December 2025</description>
</item>
<item>
<title>Mercer Convertible Securities Conversion and Amendment</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/mercer-convertible-securities-conversion-and-amendment</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/mercer-convertible-securities-conversion-and-amendment</guid>
<pubDate>Thu, 08 Jan 2026 04:28:10 GMT</pubDate>
<description>Mercer Convertible Securities Conversion and Amendment</description>
</item>
<item>
<title>Positive Final WSU Trial Results To Support IND Submission</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/positive-final-wsu-trial-results-to-support-ind-submission</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/positive-final-wsu-trial-results-to-support-ind-submission</guid>
<pubDate>Mon, 01 Dec 2025 09:52:05 GMT</pubDate>
<description>Positive Final WSU Trial Results To Support IND Submission</description>
</item>
<item>
<title>Positive Results Received from WSU on MagSense Dosage</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/positive-results-received-from-wsu-on-magsense-dosage</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/positive-results-received-from-wsu-on-magsense-dosage</guid>
<pubDate>Wed, 05 Nov 2025 03:53:15 GMT</pubDate>
<description>Positive Results Received from WSU on MagSense Dosage</description>
</item>
<item>
<title>Appendix 4C and Quarterly Activities Report - September 2025</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4c-and-quarterly-activities-report-september-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4c-and-quarterly-activities-report-september-2025-1</guid>
<pubDate>Tue, 21 Oct 2025 03:03:16 GMT</pubDate>
<description>Appendix 4C and Quarterly Activities Report - September 2025</description>
</item>
<item>
<title>Imagion Biosystems HER2 Breast Cancer Program Update</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/imagion-biosystems-her2-breast-cancer-program-update</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/imagion-biosystems-her2-breast-cancer-program-update</guid>
<pubDate>Tue, 07 Oct 2025 03:07:06 GMT</pubDate>
<description>Imagion Biosystems HER2 Breast Cancer Program Update</description>
</item>
<item>
<title>Ph2 Manufacturing & Imaging Optimisation Activities Commence</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/ph2-manufacturing-and-imaging-optimisation-activities-commence</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/ph2-manufacturing-and-imaging-optimisation-activities-commence</guid>
<pubDate>Mon, 08 Sep 2025 03:38:23 GMT</pubDate>
<description>Ph2 Manufacturing & Imaging Optimisation Activities Commence</description>
</item>
<item>
<title>Appendix 4D and Half-yearly Financial Report</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4d-and-half-yearly-financial-report-6</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4d-and-half-yearly-financial-report-6</guid>
<pubDate>Wed, 27 Aug 2025 11:11:06 GMT</pubDate>
<description>Appendix 4D and Half-yearly Financial Report</description>
</item>
<item>
<title>IBX Secures Firm Commitments for A$3.5m Capital Raising</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/ibx-secures-firm-commitments-for-adollar35m-capital-raising</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/ibx-secures-firm-commitments-for-adollar35m-capital-raising</guid>
<pubDate>Mon, 04 Aug 2025 03:55:11 GMT</pubDate>
<description>IBX Secures Firm Commitments for A$3.5m Capital Raising</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/trading-halt-1256</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/trading-halt-1256</guid>
<pubDate>Thu, 31 Jul 2025 03:28:30 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>Appendix 4C and Quarterly Activities Report - June 2025</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4c-and-quarterly-activities-report-june-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4c-and-quarterly-activities-report-june-2025-2</guid>
<pubDate>Tue, 29 Jul 2025 03:49:20 GMT</pubDate>
<description>Appendix 4C and Quarterly Activities Report - June 2025</description>
</item>
<item>
<title>Imagion MagSense Breast Cancer Program Phase 2 Trial Update</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/imagion-magsense-breast-cancer-program-phase-2-trial-update</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/imagion-magsense-breast-cancer-program-phase-2-trial-update</guid>
<pubDate>Tue, 15 Jul 2025 03:47:13 GMT</pubDate>
<description>Imagion MagSense Breast Cancer Program Phase 2 Trial Update</description>
</item>
<item>
<title>Imagion Receive Positive FDA Feedback for HER2 Phase 2 Trial</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/imagion-receive-positive-fda-feedback-for-her2-phase-2-trial</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/imagion-receive-positive-fda-feedback-for-her2-phase-2-trial</guid>
<pubDate>Thu, 10 Jul 2025 03:53:14 GMT</pubDate>
<description>Imagion Receive Positive FDA Feedback for HER2 Phase 2 Trial</description>
</item>
<item>
<title>Appendix 4C and Quarterly Activities Report - March 2025</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4c-and-quarterly-activities-report-march-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4c-and-quarterly-activities-report-march-2025-2</guid>
<pubDate>Wed, 30 Apr 2025 08:11:07 GMT</pubDate>
<description>Appendix 4C and Quarterly Activities Report - March 2025</description>
</item>
<item>
<title>Appendix 4E and 2024 Financial Report</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4e-and-2024-financial-report-3</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/appendix-4e-and-2024-financial-report-3</guid>
<pubDate>Fri, 28 Feb 2025 09:32:15 GMT</pubDate>
<description>Appendix 4E and 2024 Financial Report</description>
</item>
<item>
<title>Imagion Initiates Manufacturing of Drug for Phase 2 Study</title>
<link>https://6ix.com/company/imagion-biosystems-ltd/news/imagion-initiates-manufacturing-of-drug-for-phase-2-study</link>
<guid isPermaLink="true">https://6ix.com/company/imagion-biosystems-ltd/news/imagion-initiates-manufacturing-of-drug-for-phase-2-study</guid>
<pubDate>Wed, 19 Feb 2025 02:40:12 GMT</pubDate>
<description>Imagion Initiates Manufacturing of Drug for Phase 2 Study</description>
</item>
</channel>
</rss>